Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2013

01.01.2013 | Bone and Soft Tissue Sarcomas

Pediatric and Adolescent Synovial Sarcoma: Multivariate Analysis of Prognostic Factors and Survival Outcomes

verfasst von: Eric J. Stanelle, MD, Emily R. Christison-Lagay, MD, John H. Healey, MD, Samuel Singer, MD, Paul A. Meyers, MD, Michael P. La Quaglia, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Treatment of synovial sarcoma (SS) is challenging because of its unpredictable clinical behavior. We reviewed our institutional experience with pediatric SS to identify prognostic indicators and survival outcomes.

Methods

We retrospectively reviewed all pediatric/adolescent patients (age <22 years) with confirmed SS treated from 1970 to 2010. Patient and clinical characteristics were evaluated for prognostic significance and survival outcomes.

Results

We identified 111 patients. The median age was 15.4 years. Sixty-seven tumors (60 %) were monophasic, 42 (38 %) were biphasic, and 2 (2 %) were of unknown histology. Median follow-up was 5.3 years (range 0.8–36.8 years), 5-year overall survival (OS) was 73 %, and 10-year OS was 65 %. Greater tumor size (stratified as ≤5 cm, >5 cm, or ≥10 cm) (P = 0.001) and depth (P = 0.03) correlated with decreased OS. Primary tumor location in the upper extremity correlated with increased OS when compared with lower-extremity and central lesions (P = 0.05). Bone and/or neurovascular invasion negatively impacted survival (P = 0.02). Multivariate analysis revealed that tumor size (trichotomized) was the dominant and sole factor in discriminating survival risk. Neither radiotherapy nor chemotherapy correlated with improved 5-year survival.

Conclusions

Tumor size, depth, invasion, and primary location affect survival in pediatric SS. The role of radiotherapy and chemotherapy for SS warrants future study.
Literatur
1.
Zurück zum Zitat Ries LAG, Smith MA, Gurney JG, et al. editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. NIH Pub. No. 99-4649. Bethesda: National Cancer Institute, SEER Program; 1999. Ries LAG, Smith MA, Gurney JG, et al. editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. NIH Pub. No. 99-4649. Bethesda: National Cancer Institute, SEER Program; 1999.
2.
Zurück zum Zitat Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer. 1987;60:1800–8.PubMedCrossRef Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer. 1987;60:1800–8.PubMedCrossRef
3.
Zurück zum Zitat Andrassy RJ, Okcu MF, Despa S, et al. Synovial sarcoma in children: surgical lessons from a single institution and review of the literature. J Am Coll Surg. 2001;192:305–13.PubMedCrossRef Andrassy RJ, Okcu MF, Despa S, et al. Synovial sarcoma in children: surgical lessons from a single institution and review of the literature. J Am Coll Surg. 2001;192:305–13.PubMedCrossRef
4.
Zurück zum Zitat Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol. 2003;21:1602–11.PubMedCrossRef Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol. 2003;21:1602–11.PubMedCrossRef
5.
Zurück zum Zitat Brecht IB, Ferrari A, Int-Veen C, et al. Grossly resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative groups: discussion on the role of adjuvant therapies. Pediatr Blood Cancer. 2006;46:11–7.PubMedCrossRef Brecht IB, Ferrari A, Int-Veen C, et al. Grossly resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative groups: discussion on the role of adjuvant therapies. Pediatr Blood Cancer. 2006;46:11–7.PubMedCrossRef
6.
Zurück zum Zitat Sultan I, Rodriguez-Galindo C, Saab R, et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115:3537–47.PubMedCrossRef Sultan I, Rodriguez-Galindo C, Saab R, et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115:3537–47.PubMedCrossRef
7.
Zurück zum Zitat Schmidt D, Thum P, Harms D, et al. Synovial sarcoma in children and adolescents. A report from the Kiel Pediatric Tumor Registry. Cancer. 1991;67:1667–72.PubMedCrossRef Schmidt D, Thum P, Harms D, et al. Synovial sarcoma in children and adolescents. A report from the Kiel Pediatric Tumor Registry. Cancer. 1991;67:1667–72.PubMedCrossRef
8.
Zurück zum Zitat Ladenstein R, Treuner J, Koscielniak E, et al. Synovial sarcoma of childhood and adolescence. Report of the German CWS-81 study. Cancer. 1993;71:3647–55.PubMedCrossRef Ladenstein R, Treuner J, Koscielniak E, et al. Synovial sarcoma of childhood and adolescence. Report of the German CWS-81 study. Cancer. 1993;71:3647–55.PubMedCrossRef
9.
Zurück zum Zitat Pappo AS, Fontanesi J, Luo X, et al. Synovial sarcoma in children and adolescents: the St Jude Children’s Research Hospital experience. J Clin Oncol. 1994;12:2360–6.PubMed Pappo AS, Fontanesi J, Luo X, et al. Synovial sarcoma in children and adolescents: the St Jude Children’s Research Hospital experience. J Clin Oncol. 1994;12:2360–6.PubMed
10.
Zurück zum Zitat Ferrari A, Casanova M, Massimino M, et al. Synovial sarcoma: report of a series of 25 consecutive children from a single institution. Med Pediatr Oncol. 1999;32:32–7.PubMedCrossRef Ferrari A, Casanova M, Massimino M, et al. Synovial sarcoma: report of a series of 25 consecutive children from a single institution. Med Pediatr Oncol. 1999;32:32–7.PubMedCrossRef
11.
Zurück zum Zitat Okcu MF, Despa S, Choroszy M, et al. Synovial sarcoma in children and adolescents: thirty-three years of experience with multimodal therapy. Med Pediatr Oncol. 2001;37:90–6.PubMedCrossRef Okcu MF, Despa S, Choroszy M, et al. Synovial sarcoma in children and adolescents: thirty-three years of experience with multimodal therapy. Med Pediatr Oncol. 2001;37:90–6.PubMedCrossRef
12.
Zurück zum Zitat Harmer MH, editor. TNM classification of malignant tumours (3rd rev ed). Geneva: The International Union Against Cancer; 1982. Harmer MH, editor. TNM classification of malignant tumours (3rd rev ed). Geneva: The International Union Against Cancer; 1982.
13.
Zurück zum Zitat LaQuaglia MP, Ghavimi F, Penenberg D, et al. Factors predictive of mortality in pediatric extremity rhabdomyosarcoma. J Pediatr Surg. 1990;25:238–44.PubMedCrossRef LaQuaglia MP, Ghavimi F, Penenberg D, et al. Factors predictive of mortality in pediatric extremity rhabdomyosarcoma. J Pediatr Surg. 1990;25:238–44.PubMedCrossRef
14.
Zurück zum Zitat Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000;18:2087–94.PubMed Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000;18:2087–94.PubMed
15.
Zurück zum Zitat Brennan B, Stevens M, Kelsey A, et al. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children’s Cancer and Leukaemia Group between 1991 and 2006. Pediatr Blood Cancer. 2010;55:85–90.PubMed Brennan B, Stevens M, Kelsey A, et al. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children’s Cancer and Leukaemia Group between 1991 and 2006. Pediatr Blood Cancer. 2010;55:85–90.PubMed
16.
Zurück zum Zitat Canter RJ, Qin LX, Maki RG, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14:8191–7.PubMedCrossRef Canter RJ, Qin LX, Maki RG, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14:8191–7.PubMedCrossRef
17.
Zurück zum Zitat Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135–140.PubMed Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135–140.PubMed
18.
Zurück zum Zitat Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998;338:153–60.PubMedCrossRef Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998;338:153–60.PubMedCrossRef
Metadaten
Titel
Pediatric and Adolescent Synovial Sarcoma: Multivariate Analysis of Prognostic Factors and Survival Outcomes
verfasst von
Eric J. Stanelle, MD
Emily R. Christison-Lagay, MD
John H. Healey, MD
Samuel Singer, MD
Paul A. Meyers, MD
Michael P. La Quaglia, MD
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2587-9

Weitere Artikel der Ausgabe 1/2013

Annals of Surgical Oncology 1/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.